Romiplostim treatment for children with immune thrombocytopenia: Results of an integrated database of five clinical trials.

Michael D TarantinoJenny DespotovicJohn RoyJohn GraingerNichola CooperDonald BeamAshok RajAlexey A MaschanJune KimMelissa Eisen

Published in: Pediatric blood & cancer (2020)

Across five pediatric clinical trials, romiplostim was well tolerated. Most patients had a platelet response; some maintained responses for at least 6 months while withholding all ITP therapy.

Keyphrases

clinical trial
end stage renal disease
newly diagnosed
ejection fraction
prognostic factors
randomized controlled trial
phase ii
stem cells
open label
patient reported outcomes
bone marrow
phase iii
adverse drug